Pfizer's 6.3% Dividend Yield: Sustainability Concerns Amid Pipeline Setbacks

Pfizer (NYSE: PFE) is currently facing significant investor skepticism as its share price has plummeted 55% from its late 2021 peak. This decline has inflated the company's dividend yield to 6.3%, far exceeding the pharmaceutical industry average of 1.7%. The downward pressure is largely attributed to the company's struggle to maintain the momentum gained during the COVID-19 vaccine surge. Furthermore, the abandonment of an internally developed GLP-1 weight-loss drug candidate has left Pfizer trailing behind competitors in one of the market's most anticipated therapeutic areas. Financial metrics suggest potential strain on the dividend. The trailing 12-month dividend payout ratio ended 2025 at 126%, while the cash dividend payout ratio stood at 107%. Both figures indicate that the company is paying out more than it is earning, potentially necessitating increased debt to sustain payments in the short term. Despite these headwinds, Pfizer maintains a $155 billion market capitalization and continues to pivot its strategy. The company has recently acquired a firm with a promising GLP-1 candidate and is expanding its focus toward oncology and migraine treatments to diversify its revenue streams. Management has explicitly stated a long-term goal of maintaining the dividend in its 2025 earnings presentation. However, the disparity between Pfizer's yield and the industry average reflects a market-priced risk that the dividend could be cut if new drug pipelines fail to materialize.